Massive Bio Raises $9 Million to Scale Growth and Fuel Global Expansion of Its AI-Enabled Oncology Clinical Trial Platform
businesswire.com
news
2022-06-02 00:00:00

June 02, 2022 08:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial enrollment, raised $9 million co-led by Revo Capital and Kenan Turnacioğlu, Chair of Board of Directors PaigeAI, with additional participation from DEG – Deutsche Investitions- und Entwicklungsgesellschaft mbH, the German Development Finance Institution.



This investment will enable the company to further scale its operations globally, invest in marketing, and launch additional non-status quo products in oncology clinical trial enrollment with its data-rich platform.
